Treats a confirmed diagnosis of Type 1 Gaucher disease. Sold as Elelyso. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Taliglucerase Alfa (sold as Elelyso), first approved May 1, 2012, with 3 new uses approved and 0 published complete response letters.
| Elelyso | Part B | $4.2M | -16% | 0 |
| Elelyso | Part D | $2.6M | -8% | 0 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Pfizer